MX2022000297A - Formulacion de naltrexona. - Google Patents

Formulacion de naltrexona.

Info

Publication number
MX2022000297A
MX2022000297A MX2022000297A MX2022000297A MX2022000297A MX 2022000297 A MX2022000297 A MX 2022000297A MX 2022000297 A MX2022000297 A MX 2022000297A MX 2022000297 A MX2022000297 A MX 2022000297A MX 2022000297 A MX2022000297 A MX 2022000297A
Authority
MX
Mexico
Prior art keywords
naltrexone formulation
naltrexone
present
composition
formulation
Prior art date
Application number
MX2022000297A
Other languages
English (en)
Inventor
Venkataramana Naidu
Alkeshkumar Narayanbhai Patel
Manish Mavjibhai Patel
Manishkumar Jayantibhai Chauhan
Original Assignee
Intas Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intas Pharmaceuticals Ltd filed Critical Intas Pharmaceuticals Ltd
Publication of MX2022000297A publication Critical patent/MX2022000297A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Abstract

La presente invención se refiere a una composición farmacéutica estable y sin lactosa que comprende naltrexona o su sal farmacéuticamente aceptable. Además, la presente invención proporciona un proceso para la preparación de dicha composición y su uso para el tratamiento de la enfermedad de Crohn.
MX2022000297A 2019-07-10 2020-07-07 Formulacion de naltrexona. MX2022000297A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201921027547 2019-07-10
PCT/IB2020/056364 WO2021005501A1 (en) 2019-07-10 2020-07-07 Naltrexone formulation

Publications (1)

Publication Number Publication Date
MX2022000297A true MX2022000297A (es) 2022-04-25

Family

ID=72145422

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022000297A MX2022000297A (es) 2019-07-10 2020-07-07 Formulacion de naltrexona.

Country Status (8)

Country Link
US (1) US20220273645A1 (es)
EP (1) EP3996691A1 (es)
AU (1) AU2020309829A1 (es)
BR (1) BR112022000218A2 (es)
CA (1) CA3145794A1 (es)
MX (1) MX2022000297A (es)
WO (1) WO2021005501A1 (es)
ZA (1) ZA202200331B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022173402A1 (en) * 2021-02-09 2022-08-18 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi A film coated tablet comprising naltrexone hydrochloride

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3332950A (en) 1963-03-23 1967-07-25 Endo Lab 14-hydroxydihydronormorphinone derivatives
US6194382B1 (en) 1999-03-03 2001-02-27 Albert Einstein College Of Medicine Of Yeshiva University Method and composition for treating irritable bowel syndrome using low doses of opioid receptor antagonists
EP1935421A1 (en) * 2000-02-08 2008-06-25 Euro-Celtique S.A. Controlled-release compositions containing opioid agonist and antagonist
CN1423559A (zh) * 2000-02-08 2003-06-11 欧罗赛铁克股份有限公司 包含阿片样激动剂和拮抗剂的控释组合物
WO2001085257A2 (en) 2000-05-05 2001-11-15 Pain Therapeutics, Inc. Opioid antagonist compositions and dosage forms
CN1652752A (zh) 2002-03-14 2005-08-10 欧罗赛铁克股份有限公司 盐酸纳曲酮组合物
EP2012790A4 (en) 2006-04-19 2009-07-01 Smith Jill P TREATMENT OF INFLAMMATORY AND ULCEROUS DISEASES OF THE COLON USING OPIOID ANTAGONISTS
AR079862A1 (es) * 2010-01-08 2012-02-22 Eurand Inc Composicion de topiramato con sabor enmascarado, un comprimido desintegrable oralmente que comprende la misma y metodo de preparacion
WO2016125108A1 (en) * 2015-02-07 2016-08-11 Intas Pharmaceuticals Ltd. Bilayer pharmaceutical composition for the treatment of obesity
EP3939570A1 (en) * 2016-02-18 2022-01-19 Immune Therapeutics, Inc. Naltrexone for treating or preventing autoimmune and inflammatory diseases

Also Published As

Publication number Publication date
AU2020309829A1 (en) 2022-01-20
EP3996691A1 (en) 2022-05-18
BR112022000218A2 (pt) 2022-02-22
US20220273645A1 (en) 2022-09-01
ZA202200331B (en) 2023-11-29
WO2021005501A1 (en) 2021-01-14
CA3145794A1 (en) 2021-01-14

Similar Documents

Publication Publication Date Title
PH12017501421A1 (en) Pharmaceutical compositions comprising n-(3,5-dimethoxyphenyl)-n`-(1-methylethyl)-n-[3-(1-methyl-1h-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine
MX2021004431A (es) Procesos novedosos.
MX2019012884A (es) Terapia de combinacion.
MX2022003102A (es) Degradadores bifuncionales de brd9 y sus metodos de uso.
PH12021550992A1 (en) Compounds, pharmaceutical compositions, and methods of preparing compounds and of their use as atr kinase inhibitors
PH12017500479B1 (en) Liquid inhalation formulation comprising rpl554
MX2021005945A (es) Ureas ciclicas.
MX2021002321A (es) Nuevos metodos.
PH12020500543A1 (en) Nonracemic mixtures and uses thereof
CR20210532A (es) Protacs que degradan el receptor de estrógeno
MX2021002322A (es) Nuevos metodos.
PH12019502510A1 (en) Pharmaceutical composition and pharmaceutical dosage form comprising (e)-4-(2-(aminomethyl)-3-fluoroallyloxy)-n-tert-butylbenzamide, process for their preparation, methods for treating and uses thereof
ZA202200331B (en) Naltrexone formulation
MX2018014185A (es) Combinacion de antagonistas puros del receptor 5 ht6 con inhibidores de la acetilcolinesterasa.
MXPA03000439A (es) Nueva forma de (r)-n-(5-metil -8-(4-metilpiperazin -1-il) -1,2,3,4-tetrahidro-2-naftil) -4-morfolinobenzamida.
MX2021011986A (es) Metodos de tratamiento de dolor neuropatico.
MX2018013969A (es) Combinacion de antagonistas del receptor 5-ht6 puro con un antagonista del receptor nmda.
PL425832A1 (pl) Genisteina oraz jej kompozycja do zastosowania w leczeniu choroby Alzheimera
MX2023006235A (es) Composiciones para administracion de farmacos y metodos de uso de las mismas.
MX2021014093A (es) Composiciones y metodos para tratar el mal de alzheimer y la enfermedad de parkinson.
NZ775905A (en) Pyrrolo-pyridazine derivatives as muscarinic m1 receptor positive allosteric modulators
MX2020007062A (es) Composiciones farmacéuticas para la piel tópicas que contienen cerdulatinib y usos de estas.
EA202090416A1 (ru) Способы лечения симптомов гастропареза с использованием велусетрага
WO2019104062A8 (en) Polymorphs and uses thereof
ZA202200330B (en) Pharmaceutical composition of imatinib